Literature DB >> 30471053

Long-term outcomes of renal function after radioactive iodine therapy for thyroid cancer according to preparation method: thyroid hormone withdrawal vs. recombinant human thyrotropin.

Yoon Young Cho1,2,3, Soo Kyoung Kim1,2, Jung Hwa Jung1,2, Jong Ryeal Hahm1,2, Tae Hyuk Kim4, Jae Hoon Chung4, Sun Wook Kim5.   

Abstract

PURPOSE: Long-term effects of iatrogenic hypothyroidism on renal function from thyroid hormone withdrawal during radioactive iodine therapy (RAIT) have not been studied, especially in subjects with mildly impaired renal function. We compared renal function in thyroid cancer subjects according to preparation method of either thyroid hormone withdrawal (THW) or injection of recombinant human thyrotropin (rhTSH).
METHODS: This retrospective study enrolled 241 thyroidectomized patients (rhTSH group, n = 87 and THW group, n = 154). Changes in glomerular filtration rate (GFR) were measured prior to surgery, at the time of RAIT, and during a regular follow-up at least one year after RAIT.
RESULTS: Baseline renal function was comparable between the rhTSH group and the THW group (91.4 mL/min/1.73 m2 vs. 92.4 mL/min/1.73 m2). At the time of RAIT, GFR was significantly decreased in the THW group (70.6 mL/min/1.73 m2, -23.6%), whereas renal function was preserved in the rhTSH group (85.4 mL/min/1.73 m2, -6.6%). In the THW group, renal function was fully recovered within 6 months after RAIT and was maintained up to 24 months, even in subjects with baseline GFR less than 90 mL/min/1.73 m2.
CONCLUSIONS: THW for RAIT preparation induced considerable reduction in renal function, but this change was transient. In contrast, injection of rhTSH did not decrease renal function, making it a good option for RAIT preparation for subjects with renal dysfunction.

Entities:  

Keywords:  Radioactive iodine therapy; Recombinant human thyrotropin; Renal function; Thyroid hormone withdrawal

Year:  2018        PMID: 30471053     DOI: 10.1007/s12020-018-1807-x

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  21 in total

1.  Effect of thyroxine replacement on creatinine, insulin-like growth factor 1, acid-labile subunit, and vascular endothelial growth factor.

Authors:  Christoph Schmid; Michael Brändle; Cornelia Zwimpfer; Jürgen Zapf; Peter Wiesli
Journal:  Clin Chem       Date:  2004-01       Impact factor: 8.327

2.  Changes in renal function in primary hypothyroidism.

Authors:  J Montenegro; O González; R Saracho; R Aguirre; O González; I Martínez
Journal:  Am J Kidney Dis       Date:  1996-02       Impact factor: 8.860

3.  Consistent reversible elevations of serum creatinine levels in severe hypothyroidism.

Authors:  S H Kreisman; J V Hennessey
Journal:  Arch Intern Med       Date:  1999-01-11

4.  Effects of thyroid hormones on heart and kidney functions.

Authors:  G Capasso; G De Tommaso; A Pica; P Anastasio; J Capasso; R Kinne; N G De Santo
Journal:  Miner Electrolyte Metab       Date:  1999 Jan-Apr

5.  Thyroid hormone replacement therapy for primary hypothyroidism leads to significant improvement of renal function in chronic kidney disease patients.

Authors:  Yuji Hataya; Shuta Igarashi; Takafumi Yamashita; Yasato Komatsu
Journal:  Clin Exp Nephrol       Date:  2012-11-17       Impact factor: 2.801

6.  Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy.

Authors:  N Gopalakrishna Iyer; Luc G T Morris; R Michael Tuttle; Ashok R Shaha; Ian Ganly
Journal:  Cancer       Date:  2011-03-22       Impact factor: 6.860

7.  Changes in glomerulotubular dimensions, single nephron glomerular filtration rates and the renin-angiotensin system in hypothyroid rats.

Authors:  S E Bradley; J B Coelho; J E Sealey; K D Edwards; F Stéphan
Journal:  Life Sci       Date:  1982 Feb 15-22       Impact factor: 5.037

8.  [Expression of AP-1 and TGF-beta1 in kidney of iodine deficient rats and its significance].

Authors:  Yong-Hong Dai; Jun Zhang; Chang-Jie Liu; Hui Fang
Journal:  Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi       Date:  2009-09

9.  Elevated risks of subsequent primary malignancies in patients with thyroid cancer: a nationwide, population-based study in Korea.

Authors:  Yoon Young Cho; Jiwon Lim; Chang-Mo Oh; Junsun Ryu; Kyu-Won Jung; Jae Hoon Chung; Young-Joo Won; Sun Wook Kim
Journal:  Cancer       Date:  2014-09-15       Impact factor: 6.860

10.  The Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation does not improve the underestimation of Glomerular Filtration Rate (GFR) in people with diabetes and preserved renal function.

Authors:  Richard J MacIsaac; Elif I Ekinci; Erosha Premaratne; Zhong X Lu; Jas-Mine Seah; Yue Li; Ray Boston; Glenn M Ward; George Jerums
Journal:  BMC Nephrol       Date:  2015-12-03       Impact factor: 2.388

View more
  1 in total

1.  Evaluation of SNA001, a Novel Recombinant Human Thyroid Stimulating Hormone Injection, in Patients With Differentiated Thyroid Carcinoma.

Authors:  Yushen Gu; Hongrong Xu; Yanling Yang; Yan Xiu; Pengcheng Hu; Min Liu; Xiangqing Wang; Jun Song; Yan Di; Jian Wang; Xiaoxia Zhang; Tao Xu; Xuening Li; Hongcheng Shi
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-17       Impact factor: 5.555

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.